Komori
Chordia Therapeutics (190A) · RiskFirst stated

Foreign Exchange Risk from Foreign-Currency Transactions with Overseas Outsourcing Providers and Others

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Higher Outsourcing Costs from Exchange-Rate Fluctuations via Overseas VendorsA theme 12 companies write about · 12 as a headwind · 0 as a tailwind

4 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「In the research and development of pharmaceuticals, the Company also uses contractors overseas and conducts transactions denominated in foreign currencies. As a result, some of the Company's transactions are exposed to foreign exchange risk.」

    The risk that greater-than-expected foreign exchange movements from foreign-currency transactions with overseas contractors could affect operating results and financial position was disclosed separately for the first time.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Foreign Exchange Risk from Foreign-Currency Transactions with Overseas Outsourcing Providers and Others | Chordia Therapeutics Inc. (190A) | Komori